Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

529 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Factors associated with long-term antibody response after COVID-19 vaccination in patients treated with systemic treatment for solid tumors.
Oosting SF, van der Veldt AAM, Fehrmann RSN, Bhattacharya A, van Binnendijk RS, GeurtsvanKessel CH, Dingemans AC, Smit EF, Hiltermann TJN, den Hartog G, Jalving M, Westphal TT, de Wilt F, Ernst SM, Boerma A, van Zijl L, Rimmelzwaan GF, Kvistborg P, van Els CACM, Rots NY, van Baarle D, Haanen JBAG, de Vries EGE. Oosting SF, et al. Among authors: smit ef. ESMO Open. 2023 Aug;8(4):101599. doi: 10.1016/j.esmoop.2023.101599. Epub 2023 Jun 21. ESMO Open. 2023. PMID: 37450950 Free PMC article. No abstract available.
One-year data on immunogenicity and breakthrough infections in patients with solid tumors vaccinated against COVID-19 during systemic cancer treatment.
van der Veldt AAM, Oosting SF, Fehrmann RSN, GeurtsvanKessel CH, van Binnendijk RS, Dingemans AC, Smit EF, Hiltermann TJN, Hartog GD, Jalving M, Westphal TT, Bhattacharya A, de Wilt F, Ernst SM, Boerma A, van Zijl L, Rimmelzwaan GF, Kvistborg P, van Els CACM, Rots NY, van Baarle D, Haanen JBAG, de Vries EGE. van der Veldt AAM, et al. Among authors: smit ef. ESMO Open. 2023 Feb;8(1):100785. doi: 10.1016/j.esmoop.2023.100785. Epub 2023 Jan 10. ESMO Open. 2023. PMID: 36764094 Free PMC article. No abstract available.
Combined analysis of circulating tumor DNA and tumor tissue to overcome osimertinib resistance (OSIRIS); the second line osimertinib cohort.
van der Wel JWT, Jebbink M, van den Broek D, Steinbusch LC, Theelen WSME, Ruiter G, Buikhuisen W, Burgers JA, Baas P, Vermeulen M, van der Noort V, Hashemi SMS, Bosch LJW, Monkhorst K, Smit EF, Boelens MC, de Langen AJ. van der Wel JWT, et al. Among authors: smit ef. Lung Cancer. 2024 Dec;198:107972. doi: 10.1016/j.lungcan.2024.107972. Epub 2024 Sep 28. Lung Cancer. 2024. PMID: 39556978
Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial.
Wolf J, Hochmair M, Han JY, Reguart N, Souquet PJ, Smit EF, Orlov SV, Vansteenkiste J, Nishio M, de Jonge M, Akerley W, Garon EB, Groen HJM, Tan DSW, Seto T, Frampton GM, Robeva A, Carbini M, Le Mouhaer S, Yovine A, Boran A, Bossen C, Yang Y, Ji L, Fairchild L, Heist RS. Wolf J, et al. Among authors: smit ef. Lancet Oncol. 2024 Oct;25(10):1357-1370. doi: 10.1016/S1470-2045(24)00441-8. Lancet Oncol. 2024. PMID: 39362249 Free article. Clinical Trial.
Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non-Small Cell Lung Cancer-Results from the Drug Rediscovery Protocol.
Verkerk K, van der Wel TJWT, Zeverijn LJ, Geurts BS, Spiekman IAC, de Wit GF, Roepman P, Jansen AML, van der Noort V, Smit EF, Hoeben A, Hendriks LEL, van den Heuvel MM, Piet B, Herder GJM, Hashemi SMS, Gelderblom H, Verheul HMW, Voest EE, de Langen AJ. Verkerk K, et al. Among authors: smit ef. Clin Cancer Res. 2024 Dec 2;30(23):5323-5332. doi: 10.1158/1078-0432.CCR-24-1925. Clin Cancer Res. 2024. PMID: 39352721 Clinical Trial.
Analytical and Clinical Validation of the Oncomine Dx Target Test to Assess HER2 Mutation Status in Tumor Tissue Samples From Patients With Non-Small Cell Lung Cancer Treated With Trastuzumab Deruxtecan in the DESTINY-Lung01 and DESTINY-Lung02 Studies.
Qi Z, Ha T, Feng W, Karnoub M, Pereira K, Shiga R, Smit EF, Goto Y, De Langen AJ, Goto K, Velasco Roth AM, Khambata-Ford S. Qi Z, et al. Among authors: smit ef. Arch Pathol Lab Med. 2024 Sep 20. doi: 10.5858/arpa.2024-0014-OA. Online ahead of print. Arch Pathol Lab Med. 2024. PMID: 39299708 Free article.
mRNA-1273 vaccination induces polyfunctional memory CD4 and CD8 T cell responses in patients with solid cancers undergoing immunotherapy or/and chemotherapy.
Gangaev A, van Sleen Y, Brandhorst N, Hoefakker K, Prajapati B, Singh A, Boerma A, van der Heiden M, Oosting SF, van der Veldt AAM, Hiltermann TJN, GeurtsvanKessel CH, Dingemans AC, Smit EF, de Vries EGE, Haanen JBAG, Kvistborg P, van Baarle D. Gangaev A, et al. Among authors: smit ef. Front Immunol. 2024 Aug 27;15:1447555. doi: 10.3389/fimmu.2024.1447555. eCollection 2024. Front Immunol. 2024. PMID: 39257577 Free PMC article.
Tertiary lymphoid structure-related immune infiltrates in NSCLC tumor lesions correlate with low tumor-reactivity of TIL products.
Castenmiller SM, Kanagasabesan N, Guislain A, Nicolet BP, van Loenen MM, Monkhorst K, Veenhof AAFA, Smit EF, Hartemink KJ, Haanen JBAG, de Groot R, Wolkers MC. Castenmiller SM, et al. Among authors: smit ef. Oncoimmunology. 2024 Aug 22;13(1):2392898. doi: 10.1080/2162402X.2024.2392898. eCollection 2024. Oncoimmunology. 2024. PMID: 39188755 Free PMC article.
529 results